Maze Therapeutics (MAZE) Stock Price, Quote, News & History

Maze Therapeutics Inc (MAZE) Stock Price, Quote, News & History

MAZENASDAQ

Trade with Public

$27.42

0.732.74%

At close: Apr 13, 5:00 PM EST

$27.66

0.240.88%

After Hours: 5:14 PM EST

Key Statistics

Open

$27.10

$27.42

Volume / Avg.

1.27M / 748.90K

Day Range

$26.72 - $28.90

52 Wk Range

6.80 - 53.65

Market Cap

$1.33B

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

Days to Cover

2.41

Recent Maze Therapeutics Inc News

Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829

Maze Therapeutics stock drops despite Phase 2 data showing uACR reductions in APOL1 kidney disease; analysts keep bullish targets.

Vandana Singh

Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential

Maze's MZE782 showed strong Phase 1 results, supporting once- or twice-daily dosing with increased amino acid excretion and no serious side effects.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-111.94M

Investing Cash Flow (TTM)

-170.96M

Financing Cash Flow (TTM)

275.34M

Free Cash Flow (TTM)

-112.73M

Capital Expenditure (TTM)

-794.00K

Net Change in Cash (TTM)

-7.57M

Valuation Metrics

Enterprise Value

$1.01B

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

PB Ratio (TTM)

3.74

Earnings Yield % (TTM)

-11.43%

Earnings Yield % (FWD)

-8.24%

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

$7.14

Company Debt

Total Debt

LT Debt

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

Total Cash

$189.25M

Debt to Equity

0.07

Issuance of Debt (TTM)

Repayment of Debt (TTM)

Key Statistics

Open

$27.10

$27.42

Volume / Avg.

1.27M / 748.90K

Day Range

$26.72 - $28.90

52 Wk Range

6.80 - 53.65

Market Cap

$1.33B

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

Days to Cover

2.41

About

Sector

Health Care

Industry

Pharmaceuticals

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Maze Therapeutics (MAZE) stock?

You can purchase shares of Maze Therapeutics (NASDAQ:MAZE) through any online brokerage.

View our list of the best stock brokerages

Who are Maze Therapeutics (MAZE) competitors?

There are no as such competitors for Maze Therapeutics.

What is the forecast, or price target, for Maze Therapeutics (MAZE) stock?

There is no analysis for Maze Therapeutics to provide a consensus price target.

What is the current price for Maze Therapeutics (MAZE)?

The stock price for Maze Therapeutics (NASDAQ: MAZE) is $27.66 last updated April 13, 2026 at 5:14 PM EDT.

Does Maze Therapeutics (MAZE) pay a dividend?

There are no upcoming dividends for Maze Therapeutics.

When is Maze Therapeutics (NASDAQ:MAZE) reporting earnings?

Maze Therapeutics does not have any upcoming earnings scheduled.

Is Maze Therapeutics (MAZE) going to split?

There is no upcoming split for Maze Therapeutics.

What sector and industry does Maze Therapeutics (MAZE) operate in?

Maze Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Key Statistics

Open

$27.10

$27.42

Volume / Avg.

1.27M / 748.90K

Day Range

$26.72 - $28.90

52 Wk Range

6.80 - 53.65

Market Cap

$1.33B

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

Days to Cover

2.41

Recent Maze Therapeutics Inc News

Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829

Maze Therapeutics stock drops despite Phase 2 data showing uACR reductions in APOL1 kidney disease; analysts keep bullish targets.

Vandana Singh

Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential

Maze's MZE782 showed strong Phase 1 results, supporting once- or twice-daily dosing with increased amino acid excretion and no serious side effects.

Vandana Singh